The latest price target for Vivos Therapeutics (NASDAQ:VVOS) was reported by Ascendiant Capital on November 20, 2024. The analyst firm set a price target for $6.60 expecting VVOS to rise to within 12 months (a possible 15.79% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Vivos Therapeutics (NASDAQ:VVOS) was provided by Ascendiant Capital, and Vivos Therapeutics reiterated their buy rating.

There is no last upgrade for Vivos Therapeutics

There is no last downgrade for Vivos Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vivos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vivos Therapeutics was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest Vivos Therapeutics (VVOS) rating was a reiterated with a price target of $6.60 to $6.60. The current price Vivos Therapeutics (VVOS) is trading at is $5.70, which is out of the analyst’s predicted range.